<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atenolol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atenolol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atenolol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8940" href="/d/html/8940.html" rel="external">see "Atenolol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11019" href="/d/html/11019.html" rel="external">see "Atenolol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F6172803"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cessation of therapy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Advise patients with coronary artery disease who are being treated with atenolol against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction (MI) and ventricular arrhythmias have been reported in patients with angina following the abrupt discontinuation of therapy with beta-blockers. The last 2 complications may occur with or without preceding exacerbation of the angina pectoris. As with other beta-blockers, when discontinuation of atenolol is planned, observe the patient carefully and advise the patient to limit physical activity to a minimum. If the angina worsens or acute coronary insufficiency develops, it is recommended that atenolol be promptly reinstituted, at least temporarily. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue atenolol therapy abruptly, even in patients treated only for hypertension.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F137426"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Tenormin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865993"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Atenolol [DSC];</li>
<li>AG-Atenolol;</li>
<li>APO-Atenol;</li>
<li>DOM-Atenolol;</li>
<li>GMD-Atenolol;</li>
<li>JAMP-Atenolol;</li>
<li>Mar-Atenolol;</li>
<li>MINT-Atenol;</li>
<li>PMS-Atenolol;</li>
<li>RIVA-Atenolol;</li>
<li>TARO-Atenolol;</li>
<li>Tenormin;</li>
<li>TEVA-Atenolol;</li>
<li>TRIA-Atenolol</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051225"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianginal Agent</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Beta-Adrenergic Blocker</span></li></ul></div>
<div class="block dop drugH1Div" id="F137451"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage should be individualized based on patient response.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a301c7db-3268-48ea-b835-70ee354fa372">Hemangioma, infantile</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemangioma, infantile:</b> Limited data available: Infants and Children &lt;3 years: Oral: Usual dose: 1 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24656727','lexi-content-ref-31759456','lexi-content-ref-24011909','lexi-content-ref-27310994','lexi-content-ref-34419523']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24656727','lexi-content-ref-31759456','lexi-content-ref-24011909','lexi-content-ref-27310994','lexi-content-ref-34419523'])">Ref</a></span>); if response is inadequate, the dose can be titrated to a maximum dose of 3 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31759456','lexi-content-ref-24011909']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31759456','lexi-content-ref-24011909'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Children and Adolescents: Oral: Initial: 0.5 to 1 mg/kg/day either once daily or divided in doses twice daily; titrate dose to effect; maximum daily dose: 2 mg/kg/<b>day</b> not to exceed 100 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15286277','lexi-content-ref-NIH.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15286277','lexi-content-ref-NIH.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="adb78e1c-c976-4f71-b011-4afe5202ea6d">Marfan syndrome, aortic-root dilation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Marfan syndrome, aortic-root dilation: </b>Limited data available: Infants ≥6 months, Children, and Adolescents: Initial: 0.5 mg/kg/<b>day</b>; titrate based on tolerability and clinical goal (eg, heart rate); maximum daily dose: 4 mg/kg/<b>day</b> not to exceed 250 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25405392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25405392'])">Ref</a></span>). Dosing interval not clearly defined in the literature; once daily or divided doses twice daily are the most common dosing intervals reported in the literature for other indications; may consider dividing doses twice daily in patients &lt;10 years of age due to shorter elimination half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Buck.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Buck.1'])">Ref</a></span>). Dosing based on a randomized clinical trial (atenolol group: n=303, mean age 11.5 ± 6.5 years) comparing aortic root growth in patients with Marfan syndrome and baseline aortic-root z score &gt;3, receiving atenolol or losartan; no significant difference in aortic-root dilation over a 3-year period was found between the two groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17892982','lexi-content-ref-25405392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17892982','lexi-content-ref-25405392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="45984449-7049-4af3-a694-011566ebd1d0">Tachycardia, supraventricular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tachycardia, supraventricular:</b> Limited data available: Infants, Children, and Adolescents: Oral: Usual dose: 0.3 to 1 mg/kg/day either once daily or in divided doses every 12 hours; maximum daily dose: 2 mg/kg/<b>day</b> not to exceed 100 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dalal.1','lexi-content-ref-8662045','lexi-content-ref-37238395','lexi-content-ref-2741832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dalal.1','lexi-content-ref-8662045','lexi-content-ref-37238395','lexi-content-ref-2741832'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63559ecb-74fc-4e35-b0bd-95b480b146f7">Thyrotoxicosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxicosis:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: 1 to 2 mg/kg/dose once daily; may increase to twice daily if needed; maximum adult dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 25 to 100 mg/dose once to twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51065094"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 1 mg/kg/dose every 24 hours; maximum adult daily dose: 50 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 1 mg/kg/dose every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>); based on adult information, maximum dose should not exceed 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7461026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7461026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Maximum dose: 1 mg/kg/dose every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>); based on adult information, maximum dose should not exceed 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7461026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7461026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intermittent hemodialysis:</b> Infants, Children, and Adolescents: Oral: Moderately dialyzable (20% to 50%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29519953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29519953'])">Ref</a></span>): Maximum dose: 1 mg/kg/dose every 48 hours; give after hemodialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). <b>Note:</b> Usual adult dose is 25 to 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Infants, Children, and Adolescents: Oral: Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6487486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6487486'])">Ref</a></span>): Maximum dose: 1 mg/kg/dose every 48 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>); based on adult information, maximum dose should not exceed 25 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51065095"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; of note, atenolol undergoes limited hepatic metabolism.</p></div>
<div class="block doa drugH1Div" id="F137431"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8940" href="/d/html/8940.html" rel="external">see "Atenolol: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For vasospastic angina, beta-blockers are not recommended; calcium channel blockers and nitrates are preferred. For nonvasospastic angina, guidelines recommend titrating dose to a resting heart rate of 55 to 60 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>), while other experts recommend a target of 60 to 70 beats per minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kannam.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kannam.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 50 mg once daily; may increase dose at weekly intervals based on frequency and severity of anginal symptoms and tolerability; usual dosage range: 50 to 100 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6086960c-10cb-4421-ba68-b5977a0bab8c">Atrial fibrillation/flutter, maintenance of ventricular rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter, maintenance of ventricular rate control (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg once daily; increase dose gradually as tolerated to achieve ventricular rate control up to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30703530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30703530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended only in patients with specific comorbidities (eg, myocardial infarction [MI], arrhythmia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg once or twice daily; titrate at ≥1 week intervals as needed based on response and tolerability up to 100 mg/day in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133354','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133354','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9c2e9a4-0ef3-4e42-9cd2-e4fce906acb0">Marfan syndrome with aortic aneurysm</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Marfan syndrome with aortic aneurysm (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>:</b> Data for specific dosing are limited but a beta-blocker is recommended to slow aortic dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322642'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 0.5 mg/<b>kg </b>once daily; titrate to maintain heart rate &lt;100 beats per minute after submaximal exercise (eg, running up and down 2 flights of stairs); doses should be rounded to the nearest 25 mg increment; usual dosage range: 25 to 100 mg/day; maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wright.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wright.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="683d5204-2f9a-4f90-86f2-dc2acc899423">Migraine, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Migraine, prevention (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An adequate trial for assessment of effect is considered to be at least 2 to 3 months at a therapeutic dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31113373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31113373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 25 mg once daily; titrate gradually (eg, every 1 to 2 weeks) based on response and tolerability up to 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22529202','lexi-content-ref-24083117','lexi-content-ref-30600979','lexi-content-ref-Schwedt.1','lexi-content-ref-26252585']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22529202','lexi-content-ref-24083117','lexi-content-ref-30600979','lexi-content-ref-Schwedt.1','lexi-content-ref-26252585'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="51b05bef-6600-468e-9957-c474e5eda739">Myocardial infarction, early treatment and secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myocardial infarction, early treatment and secondary prevention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>An<b> oral</b> beta-blocker is recommended within the first 24 hours for most patients. Patients who did not receive a beta-blocker within 24 hours of MI should be reevaluated for secondary prevention at a later date (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg twice daily; some experts suggest a starting dose of 12.5 mg once daily when there is concern for adverse effects; titrate as tolerated based on heart rate and BP up to a usual maximum dose of 100 mg/day administered in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2873379','lexi-content-ref-Rosenson.1','lexi-content-ref-Simons.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2873379','lexi-content-ref-Rosenson.1','lexi-content-ref-Simons.1','lexi-content-ref-manu.1'])">Ref</a></span>). Optimal duration of therapy is unknown; treat for a minimum of 3 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef7216b4-c42e-49e5-b6a5-ca2f1192fbf6">Supraventricular tachycardia, maintenance of ventricular rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia, multifactorial atrial tachycardia), maintenance of ventricular rate control (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 to 50 mg once daily; titrate based on response and tolerability; maximum recommended dose: 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26399663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26399663'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63559ecb-74fc-4e35-b0bd-95b480b146f7">Thyrotoxicosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thyrotoxicosis (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For control of adrenergic symptoms until euthyroidism is established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 25 to 50 mg once daily; titrate as needed to control symptoms (eg, tachycardia, palpitations, tremulousness) up to a maximum of 200 mg/day in 2 divided doses. Doses ≥50 mg/day can be administered in 2 divided doses if adrenergic symptoms become noticeable toward the end of the dosing interval with once daily dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27521067','lexi-content-ref-Ross.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27521067','lexi-content-ref-Ross.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0fefb785-b323-4dbe-959e-c590bd11ef57">Ventricular arrhythmia or ventricular premature beats, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ventricular arrhythmia or ventricular premature beats (symptomatic), prevention (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 25 mg once daily; titrate dose as needed based on response and tolerability up to a maximum dose of 200 mg/day in 1 or 2 divided doses; usual dosage range: 25 to 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29084731','lexi-content-ref-12486439','lexi-content-ref-Manolis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29084731','lexi-content-ref-12486439','lexi-content-ref-Manolis.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990655"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7461026','lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7461026','lexi-content-ref-1969642'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 30 mL/minute: Maximum dose: 50 mg daily.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Maximum dose: 25 mg daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Moderately dialyzable (20% to 50%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4031118','lexi-content-ref-7378254','lexi-content-ref-29519953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4031118','lexi-content-ref-7378254','lexi-content-ref-29519953'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Daily dosing:</i> 25 to 50 mg daily; when scheduled dose falls on a dialysis day, administer post dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Three times weekly (post dialysis) dosing:</i> Initial: 25 to 50 mg 3 times weekly administered post dialysis on dialysis days; titrate based on patient response to a maximum of 100 mg 3 times weekly administered post dialysis on dialysis days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24398888','lexi-content-ref-7461026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24398888','lexi-content-ref-7461026'])">Ref</a></span>).</p>
<p style="text-indent:0em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6487486']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6487486'])">Ref</a></span>)<b>:</b> Maximum: 25 mg daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987869"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling;  however,  atenolol undergoes minimal hepatic  metabolism.</p></div>
<div class="block arsc drugH1Div" id="F56836919"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause <b>bradycardia</b> or first, second, or third-degree atrioventricular (AV) <b>heart block </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-15234417'])">Ref</a></span>). At maintenance dosing, second- or third-degree AV block are less likely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2450898'])">Ref</a></span>). Beta-blocking agents with intrinsic sympathomimetic activity (eg, pindolol) may cause fewer AV conduction abnormalities than those without intrinsic sympathomimetic activity (eg, atenolol) due to their partial agonist effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2903649','lexi-content-ref-1977302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2903649','lexi-content-ref-1977302','lexi-content-ref-2450898'])">Ref</a></span>). In most cases (up to 72%), AV block associated with a beta-blocker will resolve upon discontinuation; however, there are reported cases of recurrent AV block and nearly 50% of patients with more severe AV block may require a permanent pacemaker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530749','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530749','lexi-content-ref-15234417'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Blockade of cardiac beta-1 adrenergic receptors results in slowed conduction and prolongation in the refractory period of the AV node. Slowing of AV conduction can lead to AV block (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162','lexi-content-ref-2450898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; one study included patients who were on beta-blocker for more than 1 month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>); however, other studies noted prolongation of the PR interval or AV nodal refractory period occurring anywhere from 1 dose to several days following treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33692921','lexi-content-ref-2897302','lexi-content-ref-2450898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33692921','lexi-content-ref-2897302','lexi-content-ref-2450898'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired AV node or sinus node conduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15288162']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15288162'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other agents that impair AV nodal conduction (eg, nondihydropyridine calcium channel blockers, digoxin, ivabradine, select antiarrhythmic agents) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27899939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27899939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hyperkalemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33692921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33692921'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment, including dialysis dependence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33692921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33692921'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bronchospasm</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective beta-blockers (eg, atenolol) have a lower risk of <b>bronchospasm</b> compared to non-cardioselective beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6127219','lexi-content-ref-27390282','lexi-content-ref-24202435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6127219','lexi-content-ref-27390282','lexi-content-ref-24202435'])">Ref</a></span>). While atenolol is associated with worsening bronchoconstriction and FEV<sub>1</sub>, there appears to be no change in overall day-to-day asthma control with use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24202435','lexi-content-ref-12519582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24202435','lexi-content-ref-12519582'])">Ref</a></span>). Of the beta-blockers, atenolol has been associated with the least incidence of asthma attacks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33432057']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33432057'])">Ref</a></span>). Concurrent use of inhaled bronchodilators and/or corticosteroids are protective against beta-blocker–induced bronchospasm in patients with chronic obstructive pulmonary disease or asthma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6127219','lexi-content-ref-27390282','lexi-content-ref-24202435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6127219','lexi-content-ref-27390282','lexi-content-ref-24202435'])">Ref</a></span>). Bronchospasm is reversible upon discontinuation or use of bronchodilators (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6127219','lexi-content-ref-24202435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6127219','lexi-content-ref-24202435'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to pharmacologic action. Beta-blocking agents can lead to airway smooth muscle constriction by antagonism of beta-2 receptors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27390282']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27390282'])">Ref</a></span>). <i></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24202435','lexi-content-ref-12519582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24202435','lexi-content-ref-12519582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Acute use (reports suggest that single doses or acute use are more likely to cause changes in FEV<sub>1</sub> compared to chronic use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24202435','lexi-content-ref-12519582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24202435','lexi-content-ref-12519582'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may cause reversible CNS effects such as <b>fatigue</b>, insomnia, vivid dreams, memory impairment, and sexual disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22813717','lexi-content-ref-4054193','lexi-content-ref-1969714','lexi-content-ref-12107602','lexi-content-ref-12117400','lexi-content-ref-3017391','lexi-content-ref-1969642','lexi-content-ref-Zacharias.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22813717','lexi-content-ref-4054193','lexi-content-ref-1969714','lexi-content-ref-12107602','lexi-content-ref-12117400','lexi-content-ref-3017391','lexi-content-ref-1969642','lexi-content-ref-Zacharias.1'])">Ref</a></span>). Sexual disorders may occur; however, patients who require beta-blocker therapy may have risk factors for erectile dysfunction (eg, coronary artery disease, heart failure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29746858','lexi-content-ref-12117400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29746858','lexi-content-ref-12117400'])">Ref</a></span>). In addition, there may be a psychosomatic component (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18654082','lexi-content-ref-14585251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18654082','lexi-content-ref-14585251'])">Ref</a></span>). Hydrophilic beta-blockers, such as atenolol, penetrate the blood-brain barrier to a lesser extent than lipophilic beta-blockers, possibly leading to a lower incidence of CNS effects; however, other studies have refuted this theory (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4054193','lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-2865153']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4054193','lexi-content-ref-1969714','lexi-content-ref-1969642','lexi-content-ref-2865153'])">Ref</a></span>). CNS effects generally resolve with dose reduction or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; exact mechanism is not fully understood. Proposed mechanisms include presence of beta receptors in the brain, affinity, and in some instances, inhibition of beta-blocking agents towards serotonin (5-HT) receptors in the brain (affecting mood and sleep), and beta-blocker–induced decreases in central sympathetic output (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8956349','lexi-content-ref-2865151','lexi-content-ref-2878741'])">Ref</a></span>). Beta-1 blockade may also impact sleep by blocking sympathetic signaling to the pineal gland, resulting in suppression of nighttime levels of melatonin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23024438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23024438'])">Ref</a></span>). Beta-blockers may cause erectile dysfunction through decreased sympathetic nervous system output and subsequent decreases in luteinizing hormone secretion and testosterone stimulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24155101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24155101'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; CNS effects often occur within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969642']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969642'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher starting doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1969714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1969714'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Potentiation/masking of hypoglycemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blockers may worsen, prolong, or cause hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Additionally, beta-blockers may mask symptoms of hypoglycemia (tremor, irritability, palpitations), making diaphoresis the only symptom unaffected by beta-blockers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>). It is unclear if nonselective or selective beta-blockers are more likely to cause hypoglycemia as data are conflicting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8184','lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6339540','lexi-content-ref-6376017','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8184','lexi-content-ref-31775749','lexi-content-ref-20067434','lexi-content-ref-85053','lexi-content-ref-6339540','lexi-content-ref-6376017','lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. Beta-blockers inhibit hepatic gluconeogenesis and glycogenolysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072','lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072','lexi-content-ref-Vue.1'])">Ref</a></span>). Beta-blockers also reduce activation of the sympathetic nervous system, therefore masking hypoglycemic symptoms that are catecholamine-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vue.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vue.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; data are limited for atenolol; onset is extrapolated from other beta blocking agents: Blood glucose recovery was significantly reduced following 1 dose or 1 day of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749','lexi-content-ref-6376011','lexi-content-ref-85053','lexi-content-ref-6376017'])">Ref</a></span>); in another study, episodes of severe hypoglycemia were reported over the course of 4 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Insulin-dependent diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2861072']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2861072'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Type 2 diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28559400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28559400'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized patients not requiring basal insulin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31775749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31775749'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Beta-blocker therapy should not be withdrawn abruptly, but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia in patients with underlying cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-37093','lexi-content-ref-1981318','lexi-content-ref-7306435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-37093','lexi-content-ref-1981318','lexi-content-ref-7306435'])">Ref</a></span>). Some studies have found an increase in propensity-adjusted mortality and cardiovascular events; however, one study did not find changes in infarct size and left ventricular function when beta-blocker was abruptly withdrawn in patients with myocardial infarction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3009050','lexi-content-ref-18617067','lexi-content-ref-1968518'])">Ref</a></span>). Additionally, another study assessing effects of abrupt withdrawal of atenolol in patients with severe angina did not show any catastrophic coronary events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3970785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3970785'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose dependent; related to the pharmacologic action. Beta blockade causes upregulation of beta-receptors, enhanced receptor sensitivity, and decreased sympathetic nervous system response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874'])">Ref</a></span>). Abrupt withdrawal leads to a transient sympathetic hyper-response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874','lexi-content-ref-6125187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874','lexi-content-ref-6125187'])">Ref</a></span>). Another proposed mechanism involves increased platelet aggregability to epinephrine and thrombin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2883874'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid/varied and transient; increases in heart rate and blood pressure appear 24 hours after abrupt withdrawal, peak after 48 hours, and subside after 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt withdrawal in chronic users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of coronary artery disease (including chronic stable angina) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2897781','lexi-content-ref-2883874']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2897781','lexi-content-ref-2883874'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Past medical history of hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37093','lexi-content-ref-1968518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37093','lexi-content-ref-1968518'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F137389"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidence rates are from studies in hypertensive patients unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (3%; in patients with acute myocardial infarction: 18%)<span class="lexi-table-link-container"> (<a aria-label="Bradycardia table link" class="lexi-table-link" data-table-id="lexi-content-bradycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bradycardia')">table 1</a>)</span><span class="table-link" style="display:none;">Bradycardia</span>, heart failure (in patients with acute myocardial infarction: 19%)<span class="lexi-table-link-container"> (<a aria-label="Heart Failure table link" class="lexi-table-link" data-table-id="lexi-content-heart-failure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-heart-failure')">table 2</a>)</span><span class="table-link" style="display:none;">Heart Failure</span>, hypotension (in patients with acute myocardial infarction: 25%), supraventricular tachycardia (in patients with acute myocardial infarction: 12%), ventricular tachycardia (in patients with acute myocardial infarction: 16%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bradycardia" frame="border" id="lexi-content-bradycardia" rules="all">
<caption style="text-align:center;">
<b>Atenolol: Adverse Reaction: Bradycardia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Conventional Therapy</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Conventional Therapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Acute myocardial infarction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">244</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Conventional therapy plus atenolol</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">164</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Heart Failure" frame="border" id="lexi-content-heart-failure" rules="all">
<caption style="text-align:center;">
<b>Atenolol: Adverse Reaction: Heart Failure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Conventional Therapy</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Conventional Therapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">24%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Acute myocardial infarction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">244</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Conventional therapy plus atenolol</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (in patients with acute myocardial infarction: 5%), atrial flutter (in patients with acute myocardial infarction: 2%), bundle branch block (in patients with acute myocardial infarction: 7%), heart block (in patients with acute myocardial infarction: 5%)<span class="lexi-table-link-container"> (<a aria-label="Heart Block table link" class="lexi-table-link" data-table-id="lexi-content-heart-block" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-heart-block')">table 3</a>)</span><span class="table-link" style="display:none;">Heart Block</span>, orthostatic hypotension (2%), pulmonary embolism (in patients with acute myocardial infarction: 1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Heart Block" frame="border" id="lexi-content-heart-block" rules="all">
<caption style="text-align:center;">
<b>Atenolol: Adverse Reaction: Heart Block</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Conventional Therapy</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Conventional Therapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Acute myocardial infarction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">244</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Conventional therapy plus atenolol</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (2%), nausea (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 4%), fatigue (≤3%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 4</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, lethargy (1%), vertigo (2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Atenolol: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Conventional Therapy</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Conventional Therapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">164</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">164</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">206</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Described as "tiredness"</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (in patients with acute myocardial infarction: 1%)<span class="lexi-table-link-container"> (<a aria-label="Bronchospasm table link" class="lexi-table-link" data-table-id="lexi-content-bronchospasm" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bronchospasm')">table 5</a>)</span><span class="table-link" style="display:none;">Bronchospasm</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bronchospasm" frame="border" id="lexi-content-bronchospasm" rules="all">
<caption style="text-align:center;">
<b>Atenolol: Adverse Reaction: Bronchospasm</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Conventional Therapy</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Atenolol)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Conventional Therapy)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Acute myocardial infarction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">244</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">233</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Conventional therapy plus atenolol</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiogenic shock</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Raynaud disease (Marshall 1976)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (Gouet 1986)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Sick sinus syndrome (Neto 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Exacerbation of psoriasis (Yilmaz 2022), psoriasiform eruption (Wakefield 1990), transient alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Impotence, Peyronie disease</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Purpuric disease, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes, increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hallucination, headache, psychosis (Viadero 1983)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance</p></div>
<div class="block coi drugH1Div" id="F137406"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to atenolol or any component of the formulation; sinus bradycardia; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; uncompensated cardiac failure</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Bradycardia (regardless of origin); cor pulmonale; hypotension; severe peripheral arterial disorders; anesthesia with agents that produce myocardial depression; Pheochromocytoma (in the absence of alpha-blockade); metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F137386"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Beta-blockers are unlikely to cause anaphylaxis; however, in susceptible patients, beta-blockers have been associated with an increase in the severity of anaphylaxis. Anaphylaxis in the presence of a beta-blocker may be severe, protracted, and resistant to conventional treatment (Lang 2008; Toogood 1987).</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Stabilize patients on heart failure regimen prior to initiation or titration of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and very careful titration. Adjustment of other medications (angiotensin-converting enzyme inhibitors and/or diuretics) may be required. Efficacy of atenolol in heart failure has not been demonstrated as with other beta-blockers.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral vascular disease (PVD) and Raynaud disease: May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud disease. Use with caution and monitor for progression of arterial obstruction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may precipitate thyroid storm. Alterations in thyroid function tests may be observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasospastic angina: Beta-blockers without alpha<sub>1</sub>-adrenergic receptor blocking activity should be avoided in patients with Prinzmetal variant angina since unopposed alpha1-adrenergic receptors mediate coronary vasoconstriction and can worsen anginal symptoms (Mayer 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>
<div class="block foc drugH1Div" id="F137398"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tenormin: 25 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F137382"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F137408"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Atenolol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.24 - $0.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.79 - $0.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.22 - $1.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Tenormin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $16.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $16.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $16.03</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865994"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tenormin: 50 mg, 100 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block exp drugH1Div" id="F137404"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>2 mg/mL Oral Suspension (ASHP Standard Concentration)</b> (ASHP 2017)</p>
<p style="text-indent:0em;margin-top:2em;">A 2 mg/mL oral suspension may be made with tablets. Crush four 50 mg tablets in a mortar and reduce to a fine powder. Add a small amount of glycerin and mix to a uniform paste. Mix while adding Ora-Sweet SF vehicle in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated amber bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label “shake well”. Stable for 90 days at room temperature.</p>
<div class="reference">Nahata MC and Pai VB. <i>Pediatric Drug Formulations.</i> 6th ed. Cincinnati, OH: Harvey Whitney Books Co; 2014.</div>
<div class="reference">Patel D, Doshi DH, Desai A. Short-term stability of atenolol in oral liquid formulations. <i>Int J Pharm Compd</i>. 1997;1(6):437-439.<span class="pubmed-id">23989440</span></div>
</div>
<div class="block admp drugH1Div" id="F52612270"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;text-align:justify;display:inline">Oral: May be administered without regard to food </p></div>
<div class="block adm drugH1Div" id="F137402"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered without regard to meals.</p></div>
<div class="block sts drugH1Div" id="F2534078"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53565535"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hypertension, alone or in combination with other agents (FDA approved in adults); long-term management of angina pectoris (FDA approved in adults); management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality (FDA approved in adults); has also been used for management of supraventricular tachycardia, infantile hemangioma, Marfan syndrome (prevention of aortic-root dilation), and thyrotoxicosis.</p></div>
<div class="block mst drugH1Div" id="F137486"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atenolol may be confused with albuterol, Altenol, timolol, Tylenol</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tenormin may be confused with Imuran, Norpramin, thiamine, Trovan</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298790"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT1, OCT2</p></div>
<div class="block dri drugH1Div" id="F137391"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ampicillin: May decrease the bioavailability of Atenolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Beta-Blockers (Beta1 Selective) may enhance the hypoglycemic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacampicillin: May decrease the bioavailability of Atenolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: Beta-Blockers may enhance the adverse/toxic effect of Cannabis. Specifically, the risk of hypoglycemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Beta-Blockers may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Increase monitoring for clinical response and adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): Beta-Blockers may diminish the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Nasal): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Oral Inhalation): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epinephrine (Racemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPINEPHrine (Systemic): Beta-Blockers (Beta1 Selective) may diminish the therapeutic effect of EPINEPHrine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may diminish the therapeutic effect of Etilefrine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etofylline: Beta-Blockers may diminish the therapeutic effect of Etofylline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May increase the serum concentration of Atenolol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers.  Management: Consider alternatives to either grass pollen allergen extract (5 grass extract) or beta-blockers in patients with indications for both agents.  Canadian product labeling specifically lists this combination as contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoproterenol: Beta-Blockers may diminish the therapeutic effect of Isoproterenol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Beta-Blockers may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Beta-Blockers may enhance the therapeutic effect of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May enhance the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the bradycardic effect of Beta-Blockers. Reserpine may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Beta-Blockers may enhance the neuromuscular-blocking effect of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: Beta-Blockers may diminish the therapeutic effect of Tasimelteon.  Management: Consider avoiding nighttime administration of beta-blockers during tasimelteon therapy due to the potential for reduced tasimelteon efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">White Birch Allergen Extract: Beta-Blockers may enhance the adverse/toxic effect of White Birch Allergen Extract. Specifically, beta-blockers may reduce the effectiveness of beta-agonists that may be required to treat systemic reactions to white birch allergen extract. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F137421"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Atenolol serum concentrations may be decreased if taken with food. Management: Administer without regard to meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F58553398"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. Atenolol is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Atenolol is effective for prevention of migraines. In general, preventive treatment for migraine in patients trying to become pregnant should be avoided. Options for patients planning a pregnancy should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data and needs of the patient should pregnancy occur. A gradual discontinuation of preventive medications is generally preferred when the decision is made to stop treatment prior to conception (ACOG 2022; AHS [Ailani 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">Impotence is noted in product labeling following postmarketing use of atenolol. As a class, outcomes from available studies evaluating beta-blockers and sexual dysfunction are inconsistent, and the negative effects on erectile function and libido are considered controversial. A clear relationship between use of beta-blockers and erectile dysfunction has not been established. Hypertension itself is associated with erectile dysfunction. Patients on a beta-blocker presenting with sexual dysfunction should be evaluated for underlying disease (Farmakis 2021; Levine 2012; Semet 2017; Terentes-Printzios 2022; Viigimaa 2020).</p></div>
<div class="block pri drugH1Div" id="F137409"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Atenolol crosses the placenta and is found in cord blood.</p>
<p style="text-indent:0em;margin-top:2em;">Maternal use of atenolol may cause harm to the fetus. Adverse events, such as bradycardia, hypoglycemia and reduced birth weight, have been observed following in utero exposure to atenolol. If maternal use of a beta-blocker is needed, monitor fetal growth during pregnancy; monitor the newborn for 48 hours after delivery for bradycardia, hypoglycemia, and respiratory depression (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">The maternal pharmacokinetic parameters of atenolol during the second and third trimesters are within the ranges reported in nonpregnant patients (Hebert 2005).</p>
<p style="text-indent:0em;margin-top:2em;">When treatment of chronic hypertension during pregnancy is indicated, atenolol is not recommended due to adverse fetal/neonatal events (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]). Atenolol is also not recommended for the treatment of atrial fibrillation or supraventricular tachycardia during pregnancy; consult current guidelines for specific recommendations (ESC [Regitz-Zagrosek 2018]).</p>
<p style="text-indent:0em;margin-top:2em;">In general, preventive treatment for migraine should be avoided during pregnancy. Options for pregnant patients should be considered as part of a shared decision-making process. Nonpharmacologic interventions should be considered initially. When needed, preventive treatment should be individualized considering the available safety data, the potential for adverse maternal and fetal events, and needs of the patient (ACOG 2022; AHS [Ailani 2021]). If preventive therapy is needed, beta-blockers may be considered (ACOG 2022) however agents other than atenolol may be preferred (CHS [Pringsheim 2012]).</p></div>
<div class="block mopp drugH1Div" id="F53565520"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure, heart rate, ECG, respiratory rate, and signs and symptoms of hypoglycemia with oral administration (especially in infants and young children).</p></div>
<div class="block pha drugH1Div" id="F137385"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitively blocks response to beta-adrenergic stimulation, selectively blocks beta<sub>1</sub>-receptors with little or no effect on beta<sub>2</sub>-receptors except at high doses</p></div>
<div class="block phk drugH1Div" id="F137405"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Beta-blocking effect: Onset: Oral: ≤1 hour; Peak effect: Oral: 2 to 4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Normal renal function: Beta-blocking effect: 12 to 24 hours; Antihypertensive effect: Oral: 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Rapid, incomplete (~50%)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Low lipophilicity; does not cross blood-brain barrier </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 6% to 16% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Limited hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Beta: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Newborns (&lt;24 hours of age) born to mothers receiving atenolol: Mean: 16 hours; up to 35 hours (Rubin 1983)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Children and Adolescents 5 to 16 years of age: Mean: 4.6 hours; range: 3.5 to 7 hours; Patients &gt;10 years of age may have longer half-life (&gt;5 hours) compared to children 5 to 10 years of age (&lt;5 hours) (Buck 1989) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Adults: Normal renal function: 6 to 7 hours, prolonged with renal impairment; End-stage renal disease (ESRD): 15 to 35 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: Oral: 2 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Feces (50%); urine (40% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51220452"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination is closely related to glomerular filtration rate. Significant accumulation occurs when CrCl falls below 35 mL/minute per 1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Total clearance is about 50% lower than in younger subjects. Half-life is markedly longer in older adults.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F137412"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Apo atenolol | Aten | Ateno | Betaten | Blokium | Glormin | Hypoten | Normoten | Novo atenol | Tenol | Tenormin | Tensotin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Apo atenolol | Atel | Atelan | Atelsta | Atenoblock | Atenolol biotenk | Atenolol eczane | Atenolol fabop | Atenolol fabra | Atenolol fecofar | Atenolol gador | Atenolol gen med | Atenolol lacefa | Atenolol microsules | Atenolol northia | Atenolol puntanos | Atenolol quesada | Atenolol vannier | Atenolol vent 3 | Fabotenol | Fada atenolol | Felobits | Lolateno | Myocord | Plenacor | Prenormine | Telvodin | Tozolden | Vericordin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atehexal | Atenolan | Atenolol genericon | Atenolol Ratiopharm | Atenolol stada artzneimittel gmbh | Atenolol-1a | Atenotyrol | Tenormin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Anselol | Apo atenolol | Atehexal | Atenolol aft | Atenolol an | Atenolol PS | Atenolol rbx | Atenolol sandoz | Atenolol-bc | Atenolol-GA | Cm atenolol | Dbl atenolol | Noten | Sbpa atenolol | Tenolten | Tenormin | Tensig | Tw atenolol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anetol | Apres | Ateloc | Atenol | Atin | Atol | B Card | Betanol | Betapress | Betasec | Bpnol | Cardilock | Cardipro | Cardisef | Carsec | Enol | Etnol | Janol | Lonet | Lopres | Lorten | Normaten | Norpress | Precinol | Recard | Tenocard | Tenol | Tenoloc | Tenolol | Tenoren | Tenormin | Tensin | Vasocard</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Atenolol eg | Atenolol eurogenerics | Atenolol Far | Atenolol Kela | Atenolol merck-generics | Atenolol Ratiopharm | Atenolol sandoz | Atenolol teva generics belgium | Atenomed | Atenotop | Athenol | Blokium | Docateno | Kelatenor | Tenormin</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Blokium | Captenol | Tensicard</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Blocotenol | Tenormin | Tredol</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ablok | Angiless | Angipress | Angitens | Atecard | Atenalon | Atenegran | Ateneo | Ateneum | Atenobal | Atenokin | Atenol | Atenolab | Atenopress | Atenorm | Atenoton | Atenuol | Atepress | Biotenor | Neotenol | Plenacor | Ritcor | Telol | Tenolon</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atenil | Atenil submite | Ateno-basan | Atenolol Adico | Atenolol genericon | Atenolol helvepharm | Atenolol sandoz | Atenolol skyepharma | Atenolol spirig | Atenolol spirig hc | Atenolol upsa | Atenolol-cophar | Cardaxen | Cardaxen 100 | Tenormin</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Atenolol denk | Betatop | Blokium | Cardinol | Normet | Novaten | Precyl | Tenolol | Tenormine | Tensicard</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Betacar | Grifotenol | Labotensil | Sotacor | Tenormin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Tenormin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Atenolol mk | Diluxen | Plenacor | Tenormin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo atenol | Ateblocor | Atehexal | Atenobene | Atenolol al | Atenolol dh | Blocotenol | Catenol | Tenormin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ate abz | Ate lich | Atebeta | Atehexal | Atendol | Ateno Isis | Ateno klast | Atenogamma | Atenolol axcount | Atenolol Billix | Atenolol denk | Atenolol freemed | Atenolol holsten | Atenolol von ct | Atenomerck | Blocotenol | Cuxanorm | Dignobeta | Duratenol | Evitocor | Falitonsin | Jenatenol | Juvental | Phamolol | Teno | Teno biochemie | Tenormin | Tonoprotect | Unibloc</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Atenolol biochemie | Atenolol merck nm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Atelol | Atenobrit | Atenofar | Atenorin b | Betabloquin | Betanolol | Blocotenol | Blokanol | Blokium | Blotenol | Carcepin | Cardaten | Corin | Cymatelol | Farbloc | Fratenolol | Nolol | Soldent | Tensil | Tensional</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">A tnolstar | Atenolol nifa | Plenacor | Tendiol | Tenormin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atehexal | Atenobene | Atenodex | Atenolan | Atenolol ns | Atenolol Ratiopharm | Atenololum | Atenolool | Atenosan | Normolol | Tenormin | Uniloc</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Atelol | Ateno | Atenoblock | Atenol | Blokium | Tenoloc | Tenormin | Tenotens | Tensolol</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atenolol alter | Atenolol Apotex | Atenolol aurovitas | Atenolol bexal | Atenolol Boi | Atenolol Cinfa | Atenolol edigen | Atenolol leo | Atenolol mundogen | Atenolol normon | Atenolol Ratiopharm | Atenolol Tarbis | Blokium | Neatenol | Tanser | Tenormin</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Ateleb | Atenol | Atenolol denk | Betafil | Cardioten | Tenomac | Tenormin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alinor | Atenblock | Atenol | Atenolol leiras | Atenolol sandoz | Atenolol tika | Tenoblock | Tenoprin | Uniloc</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atenolol accord | Atenolol actavis | Atenolol Arrow | Atenolol Bayer | Atenolol biogaran | Atenolol gnr | Atenolol irex | Atenolol ivax | Atenolol merck | Atenolol MSD | Atenolol qualimed | Atenolol Ratiopharm | Atenolol rpg | Atenolol sandoz | Atenolol teva | Atenolol zydus | Betatop | Tenormine | Xaten</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Antipressan | Atenolol A L | Atenolol Almus | Atenolol aps | Atenolol Arrow | Atenolol berk | Atenolol cox | Atenolol Kent | Atenolol sandoz | Atenolol Zanza | Presumex | Tenormin | Tenormin ls | Totamol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Azectol | Blocotenol | Fealin | Hemon | Mesonex | Mezarid | Neocardon | Silder | Synarome | Tenormin | Tradiver</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Alonet | Antipressan | Apo-Atenol | Atenolol Cinfa | Atenomel | Celonol | Corotenol | Cp atenol | Hypernol | Korus atenolol | Lo-ten | Normaten | Noten | Telol | Ten-bloka | Tenoren | Tenormin | Ternolol | Totamol | Tredol | Vascotan | Vascoten | Velorin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Atenolol Jadran | Atenolol Pliva | Ormidol | Tenormin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atenobene | Atenolol-al | Atenolol-b | Atenomel | Blokium | Huma-atenol | Prinorm | Tenormin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Betablok | Farnormin | Hiblok | Internolol | Lotenac | Tenblok | Tenormin | Tensinorm | Zumablok</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amolin | Antipressan | Atecor | Ateni | Atenogen | Atenomel | Nortenolol | Tenormin | Trantalol</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aponorm | Normalol | Normiten</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alinor | Aloten | Altol | Anol | Astanol | At-syn | Atanol | Atcom | Atecard | Atekind | Atelol | Atemarc | Aten | Atenex | Atenij | Atenkind | Atenova | Atepres | Atese | Atigal | Atmost | Atnol | Atol | Atop | Atormin | Atpark | Becardol | Benol | Beta | Betacard | Betadure | Beten | Bipinol | Bp norm | Cadpres | Catenol | Coronol | Dilpres | Enee | Entolol | G-Ten | Hibesor | Hipres | Hyten | Itel | Lakten | Latenol | Lonet | Lonol | M nol | Manoten | Nalotol | Novaten | O-beta | Odinol | Olate | Otenol | Ozoten | Pertenol | Reno | Stanol | Storatol | Tefifin | Temin | Tenase | Teno | Tenokem | Tenolol | Tenomac | Tenorex | Tenormin | Tensicard | Tensimin | Terifin | Utl | Ziblok</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Awatenol</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Tensol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atenol | Atenololo | Atenololo Actavis | Atenololo ahcl | Atenololo almus | Atenololo aurobindo | Atenololo Bouty | Atenololo doc | Atenololo eg | Atenololo Fg | Atenololo Rat | Atenololo sigma tau | Atermin | Seles beta | Tenomax | Tenormin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Blokium | Hypoten | Loten | Tenolol | Tenopress | Tenormin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alcenol harasawa | Alcenol hexal | Alcenol kayaku | Almylar | Aloteno | Atelol | Atendal | Atenemeal | Atenolol nissin | Atenolol t iwaki | Atenolol t teisan | Atenorhythm | Atenosafe | Dolru | Fellfish | Hajime | Hamiya | Katenomin | Katenomin choseido | Katenomin merck hoei | Kushisemin | Lismories | Mecrol | Metinin | Mezolmin | Mirobect | Neglies | Originol | Plablem | Ritterun | Sailagile kobayashi | Savetens | Slinstar | Tenomilol | Tenormin | Towamin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Anolol | Atecard | Aten | Atenol | Atenolol denk | Atin | Betanorm | Blokium | Cardinol | Cardioten | Catenol | Hyperlok | Lonet | Tenolol | Tenormin | Tredol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aiti | Al | Anol | Anolene | Anolex | Anolmin | Anolpin | Anorlex | Antebinol | Antevinol | Aprogen atenolol | Arandin | Asotin | Asten | Atelmin | Atelol | Atelonal | Aten | Atena | Atenal | Atendol | Ateno | Atenol | Atenolin | Atenormin | Ateronal | Atolmin | Atonic | Betarol | Betelmin | Betenol | Bitenol | Carteol | Casperol | Daewoo atenolol | Daewoong atenolol | Daewoongbio atenolol | Detent | Emtenol | Fastenol | Feron | Gl atenolol | Hana atenolol | Hiten | Kms atenolol | Latemin | Lotenal | Lozamin | Maxinol | Mytenol | Newgenpharm atenolol | Oltenol | Reyon atenolol | Scd Atenolol | Temoret | Tenal | Tenarol | Tenopress | Tenorlan | Tenormin | Withus atenolol</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Atormin | Betaten | Cardol | Corotenol | Glormin | Tenol | Tenormin | Tensotin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo atenolol | Atonium | Blokium | Cardaten | Corotenol | Tenormin | Tensotin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo atenolol | Atcardil | Atenobene | Atenodex | Atenolan | Atenolol bp | Atenosan | Betacard | Catenol | Ormidol | Synarome | Tenormin | Uniloc</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Atehexal | Atenolol eg | Athenol | Docateno | Tenormin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atcardil | Atehexal | Atenobene | Atenodex | Atenolan | Atenolol accord | Atenolol aliud | Atenolol Cinfa | Atenolol stada | Atenolol von ct | Atenosan | Betacard | Catenol | Ormidol | Synarome | Tenormin | Uniloc</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Atenor | Normatens | Normet | Tenormine | Xytenol | Zotrol</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Atcord | Atenolol degort's | Atenolol gi serral | Atoken | Biofilen | Blotex | Cartenol | Coraten | Internol | Lesaten | Min-t | Nosbal | Tenormin | Thoratoz</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-Atenol | Atebloc | Atehexal | Atekline | Atemin | Atenol | Atenolol Pharmaniaga | Aveten | Axcel atenolol | Beten | Coratol | Corotenol | Dynormin | Loten | Noten | Oraday | Pretenol | Ranlol | Renotol | Sanormin | Tenol | Tenormin | Ternolol | Uphanormin | Urosin | Vascoten | Velorin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Atenomel | Atpure 50 | Betafil | Bitenol | Eden | Eden atenolol | Pretenol | Ratenol | Sanolol | Tenolol | Tenormin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atenolol accord | Atenolol alpharma | Atenolol flx | Atenolol sandoz | Atenolol teva | Tenormin | Tenormine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alinor | Atenolol 1a pharma | Atenolol aliud | Atenolol mylan | Atenolol Ratiopharm | Atenolol sandoz | Tenormin | Tenormin ls | Uniloc</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Anselol | Apo-atenolol | Atenolol viatris | Global atenolol | Lo-ten | Loten | Tenormin</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Betaten</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Apo-Atenol | Arterium | Atenobiotech | Atenolmek | Atenolol labot | Cardaten | Tenolat | Tenormin | Tonocor</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aloten | Aten | Atenol | Atenolol Drugmakers | Atenolol stada | Cardioten | Durabeta | Myovasc | Rotelol | Serten | Tenor bloc | Tenorvas | Tensimin | Therabloc | Trubloc | Velodin | Velorin | Zenobloc</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adonax | Antolol | Atelomir | Atelor | Atelosim | Ateno-heart | Atenocard | Atenopharm | Atenorm | Atenosap | Atenoscot | Atl | Atlin | Atn | Atromin | Atson | Betanol | Betarol | Blocker | Blokium | Cardaxen | Cardi | Cardilol | Cardiolite | Cardipro | Careeb | Caricard | Cartac | Caten | Controbeat | Coxalol | Diolit | Eourmin | Eplacard | Hypernol | Iqanol | M nol | Minocard | Netolol | Nomin | Normitab | Plinol | Pulsbit | Pulse | Qunoten | Retlol | Sydlol | Tenol | Tenormax | Tenormin | Tinocard | Totamol | Tredol | Trobel | Uminol | Zafnol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo-Atenol | Atehexal | Atendol | Atenolol lph | Blocotenol | Normocard | Tenormin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Tenormin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ancoren | Atenolol labesfal | Blokium | Tenormin | Tessifol</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alfatenol | Atarox | Atenocar | Atenolol caplin point | Atenolol dallas | Atenolol emcure | Atenolol gador | Atenolol mintlab | Atenolol vivele | Betafar | Bloket | Dilapres | Fabotenol | Indoca | Plenacor | Prenormine | Terquin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Atelol | Atormin | Betaten | Glormin | Hypoten | Tenol | Tenormin | Tensotin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Atecor | Atenil | Atenocor | Atenolol arena | Atenolol lph | Azectol | Blocotenol | Ephitensin | Synarome | Vascoten</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo atenol | Aten | Atenobene | Atenol | Atenolan | Atenolol Agio | Atenolol akos | Atenolol akri | Atenolol belupo | Atenolol nycomed | Atenolol Ratiopharm | Atenolol stada | Atenolol ubf | Betacard | Betadur | Catenol | Hypoten | Prinorm | Tenolol | Tenormin | Uniloc | Vascoten | Vero atenolol</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo atenol | Atormin | Betaten | Blokium | Hypoten | Normoten | Novo atenol | Pms-atenolol | Preslo | Tenol | Tenormin | Tensotin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atenolol 2care4 | Atenolol actavis | Atenolol merck nm | Atenolol mylan | Atenolol nordic | Atenolol nycomed | Atenolol orifarm | Atenolol sandoz | Tenormin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aiti | Alonet | Apo-Atenol | Coratol | Hypernol | Normaten | Noten | Prenolol | Tenol | Tenolol | Tenormin | Urosin | Vascoten</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ormidol | Tenormin | Velorin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atehexal | Atenobene | Atenolol al | Atenolol dh | Tenormin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Apo atenolol | Atehexal | Atemin | Atenol | Atenolol Kopran | Atenolol Nida | Banolol | Betaday | Cardnol | Catinol | Coratol | Enolol | Inolol | Nolol | Nortelol | Noten | Oraday | Pharmalol | Pharoxin | Preloc | Prenolol | Tenocard | Tenocor | Tenol | Tenolol | Tenormin | Tenpress | Tenrol | Tetalin | Tinolol | Vascoten | Velorin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Atenad | Atenor | Hypoten | Inicard | Tenormine | Vascoten</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">As atens | Atolteva | Nortan | Tensinor</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aircrit | Anlipin | Apo-Atenol | Atehexal | Atelon | Atenemeal | Ateno | Atenol | Atenorhythm | Atenormin | Ateol | Atinol | Atomin | Blokium | Cinyala | Denolmin | Mirobect | Noten | Pensin | Profit | Sedamin | Selinin | Stermin | Suarolol | Swinorin | Tandate | Tenminlar | Tenol | Tenolin | Tenolmin | Tenolol | Tenomilol | Tenormin | Tiatenol | Unormin | Urosin | Vasoral | Wesipin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atenosan | Atenova | Hypoten | Sinarom | Tenolol | Tenormin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Atenolol denk | Cardinol | Catenol | Codanol | Hyperlok | Tena | Tensimin | Velorin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Atenolan | Atenolol Donier | Atenolsur | Grifotenol | Miocardox | Preventil | Tenormin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Artenolol | Atenoval | Beloc | Blokium | Ritmilan | Tenormin | Tonidol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-Atenolol | Apo-atenolol | Atenoblok | B block | B-vasc | Bio Atenolol | Hexa-blok | Ivax-atenolol | Ten-bloka | Tenopress | Tenormin | Zetenol</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Ateleb | Atenolol denk | Atormin | Betacard | Betafil | Bp norm | Corin | Hipres | Intalol | Novaten | Tenolol | Tenomac | Tenormin | Ternolol</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Hipres</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24656727">
<a name="24656727"></a>Ábarzúa-Araya A, Navarrete-Dechent CP, Heusser F, Retamal J, Zegpi-Trueba MS. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.<i> J Am Acad Dermatol</i>. 2014;70(6):1045-1049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24656727/pubmed" id="24656727" target="_blank">24656727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24398888">
<a name="24398888"></a>Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. <i>Nephrol Dial Transplant</i>. 2014;29(3):672-681. doi:10.1093/ndt/gft515<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24398888/pubmed" id="24398888" target="_blank">24398888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160823">
<a name="34160823"></a>Ailani J, Burch RC, Robbins MS; Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. <i>Headache</i>. 2021;61(7):1021-1039. doi:10.1111/head.14153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/34160823/pubmed" id="34160823" target="_blank">34160823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. Published online October 30, 2017. doi:10.1161/CIR.0000000000000549<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. <i>Pediatrics</i>. 2011;128(5):S1-S44.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19926021">
<a name="19926021"></a>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines; American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine; Society for Vascular Surgery, Fleischmann KE, Beckman JA, Buller CE, et al. 2009 ACCF/AHA focused update on perioperative beta blockade [published correction appears in <i>J Am Coll Cardiol</i>. 2012;59(24):2306]. <i>J Am Coll Cardiol</i>. 2009;54(22):2102-2128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/19926021/pubmed" id="19926021" target="_blank">19926021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35576364">
<a name="35576364"></a>American College of Obstetricians and Gynecologists (ACOG). Headaches in pregnancy and postpartum: ACOG clinical practice guideline No. 3. <i>Obstet Gynecol</i>. 2022;139(5):944-972. doi:10.1097/AOG.0000000000004766<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/35576364/pubmed" id="35576364" target="_blank">35576364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i>. 2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35058422">
<a name="35058422"></a>Bailuni Neto JJ, Siqueira BL, Machado FC, et al. BRASH Syndrome: a case report. <i>Am J Case Rep</i>. 2022;23:e934600. doi:10.12659/AJCR.934600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/35058422/pubmed" id="35058422" target="_blank">35058422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12044345">
<a name="12044345"></a>Beardmore KS, Morris JM, Gallery ED. Excretion of antihypertensive medication into human breast milk: a systematic review. <i>Hypertens Pregnancy</i>. 2002;21(1):85-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/12044345/pubmed" id="12044345" target="_blank">12044345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17175824">
<a name="17175824"></a>Becker DE, Reed KL. Essentials of local anesthetic pharmacology. <i>Anesth Prog.</i> 2006;53(3):98-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/17175824/pubmed" id="17175824" target="_blank">17175824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6636259">
<a name="6636259"></a>Bhamra RK, Thorley KJ, Vale JA, Holt DW. High-performance liquid chromatographic measurement of atenolol: methodology and clinical applications.<i> Ther Drug Monit</i>. 1983;5(3):313-318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6636259/pubmed" id="6636259" target="_blank">6636259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18410416">
<a name="18410416"></a>Brauchli YB, Jick SS, Curtin F, et al. Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study. <i>Br J Dermatol</i>. 2008;158(6):1299-1307.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/18410416/pubmed" id="18410416" target="_blank">18410416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Buck.1">
<a name="Buck.1"></a>Buck ML, Wiest D, Gillette PC, et al. Pharmacokinetics and Pharmacodynamics of Atenolol in Children. <i>Clin Pharmacol Ther</i>. 1989;46(6):629-633.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29746858">
<a name="29746858"></a>Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. <i>J Urol</i>. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/29746858/pubmed" id="29746858" target="_blank">29746858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31759456">
<a name="31759456"></a>Calderón-Castrat X, Velásquez F, Castro R, Ballona R. Oral atenolol for infantile hemangioma: case series of 46 infants. Atenolol oral en el manejo del hemangioma infantil: serie de casos de 46 pacientes. <i>Actas Dermosifiliogr (Engl Ed)</i>. 2020;111(1):59-62. doi:10.1016/j.ad.2019.03.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/31759456/pubmed" id="31759456" target="_blank">31759456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4031118">
<a name="4031118"></a>Campese VM, Feinstein EI, Gura V, Mason WD, Massry SG. Pharmacokinetics of atenolol in patients treated with chronic hemodialysis or peritoneal dialysis. <i>J Clin Pharmacol</i>. 1985;25(5):393-395. doi:10.1002/j.1552-4604.1985.tb02864.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/4031118/pubmed" id="4031118" target="_blank">4031118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22813717">
<a name="22813717"></a>Chang CH, Yang YH, Lin SJ, Su JJ, Cheng CL, Lin LJ. Risk of insomnia attributable to β-blockers in elderly patients with newly diagnosed hypertension. <i>Drug Metab Pharmacokinet</i>. 2013;28(1):53-58. doi:10.2133/dmpk.dmpk-12-rg-004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/22813717/pubmed" id="22813717" target="_blank">22813717</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23083782">
<a name="23083782"></a>Chockalingam P, Crotti L, Girardengo G, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. <i>J Am Coll Cardiol</i>. 2012;60(20):2092-2099. doi:10.1016/j.jacc.2012.07.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/23083782/pubmed" id="23083782" target="_blank">23083782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18654082">
<a name="18654082"></a>Cocco G. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect. <i>Cardiology</i>. 2009;112(3):174-177. doi:10.1159/000147951<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/18654082/pubmed" id="18654082" target="_blank">18654082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4054193">
<a name="4054193"></a>Cove-Smith JR, Kirk CA. CNS-related side-effects with metoprolol and atenolol. <i>Eur J Clin Pharmacol</i>. 1985;(28)(suppl):69-72. doi:10.1007/BF00543713<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/4054193/pubmed" id="4054193" target="_blank">4054193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3009050">
<a name="3009050"></a>Croft CH, Rude RE, Gustafson N, et al. Abrupt withdrawal of beta-blockade therapy in patients with myocardial infarction: effects on infarct size, left ventricular function, and hospital course. Circulation. 1986;73(6):1281-1290. doi:10.1161/01.cir.73.6.1281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/3009050/pubmed" id="3009050" target="_blank">3009050</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11937178">
<a name="11937178"></a>Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet</i>. 2002;359(9311):995-1003. doi:10.1016/S0140-6736(02)08089-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/11937178/pubmed" id="11937178" target="_blank">11937178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969714">
<a name="1969714"></a>Dahlöf C, Dimenäs E. Side effects of beta-blocker treatments as related to the central nervous system. <i>Am J Med Sci</i>. 1990;299(4):236-244. doi:10.1097/00000441-199004000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/1969714/pubmed" id="1969714" target="_blank">1969714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dalal.1">
<a name="Dalal.1"></a>Dalal AS, Van Hare GF. Disturbances of rate and rhythm of the heart. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 462.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24011909">
<a name="24011909"></a>de Graaf M, Raphael MF, Breugem CC, et al. Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. <i>J Plast Reconstr Aesthet Surg</i>. 2013;66(12):1732-1740. doi:10.1016/j.bjps.2013.07.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24011909/pubmed" id="24011909" target="_blank">24011909</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8184">
<a name="8184"></a>Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. <i>Br Med J</i>. 1976;2(6030):272-273. doi:10.1136/bmj.2.6030.272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/8184/pubmed" id="8184" target="_blank">8184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31775749">
<a name="31775749"></a>Dungan K, Merrill J, Long C, Binkley P. Effect of beta blocker use and type on hypoglycemia risk among hospitalized insulin requiring patients. <i>Cardiovasc Diabetol</i>. 2019;18(1):163. doi:10.1186/s12933-019-0967-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/31775749/pubmed" id="31775749" target="_blank">31775749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897781">
<a name="2897781"></a>Egstrup K. Transient myocardial ischemia after abrupt withdrawal of antianginal therapy in chronic stable angina. <i>Am J Cardiol</i>. 1988;61(15):1219-1222. doi:10.1016/0002-9149(88)91158-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2897781/pubmed" id="2897781" target="_blank">2897781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24083117">
<a name="24083117"></a>Edvardsson B. Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study. <i>Springerplus</i>. 2013;2:479. doi:10.1186/2193-1801-2-479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24083117/pubmed" id="24083117" target="_blank">24083117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eyal.1">
<a name="Eyal.1"></a>Eyal S, Kim JD, Anderson GD, et al. Atenolol pharmacokinetics and excretion in breast milk during the first 6 to 8 months postpartum. <i>J Clin Pharmacol</i>. 2010;50(11):1301-1309.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33945044">
<a name="33945044"></a>Farmakis IT, Pyrgidis N, Doundoulakis I, Mykoniatis I, Akrivos E, Giannakoulas G. Effects of major antihypertensive drug classes on erectile function: a network meta-analysis. <i>Cardiovasc Drugs Ther</i>. 2022;36(5):903-914. doi:10.1007/s10557-021-07197-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/33945044/pubmed" id="33945044" target="_blank">33945044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation.</i> 2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7378254">
<a name="7378254"></a>Flouvat B, Decourt S, Aubert P, et al. Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis. <i>Br J Clin Pharmacol</i>. 1980;9(4):379-385. doi:10.1111/j.1365-2125.1980.tb01065.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/7378254/pubmed" id="7378254" target="_blank">7378254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12107602">
<a name="12107602"></a>Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. <i>Eur J Clin Pharmacol</i>. 2002;58(3):177-180. doi:10.1007/s00228-002-0456-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/12107602/pubmed" id="12107602" target="_blank">12107602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617067">
<a name="18617067"></a>Fonarow GC, Abraham WT, Albert NM, et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. <i>J Am Coll Cardiol</i>. 2008;52(3):190-199. doi:10.1016/j.jacc.2008.03.048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/18617067/pubmed" id="18617067" target="_blank">18617067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20067434">
<a name="20067434"></a>Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. <i>Curr Med Res Opin</i>. 2010;26(3):615-629. doi:10.1185/03007990903533681<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/20067434/pubmed" id="20067434" target="_blank">20067434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6867180">
<a name="6867180"></a>Foster CA, Aston SJ .Propranolol-Epinephrine Interaction: A Potential Disaster. <i>Plast Reconstr Surg</i>. 1983;72(1):74-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6867180/pubmed" id="6867180" target="_blank">6867180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2883874">
<a name="2883874"></a>Frishman WH. Beta-adrenergic blocker withdrawal. <i>Am J Cardiol</i>. 1987;59(13):26F-32F. doi:10.1016/0002-9149(87)90038-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2883874/pubmed" id="2883874" target="_blank">2883874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903649">
<a name="2903649"></a>Frishman WH. Circulatory and metabolic aspects of beta-adrenoceptor blockade. <i>Am Heart J</i>. 1988;116(5, pt 2):1393-1400. doi:10.1016/0002-8703(88)90129-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2903649/pubmed" id="2903649" target="_blank">2903649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2910169">
<a name="2910169"></a>Gandy W. Severe epinephrine-propranolol interaction. <i>Ann Emerg Med.</i> 1989;18:98-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2910169/pubmed" id="2910169" target="_blank">2910169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1352658">
<a name="1352658"></a>Geffner DL, Hershman JM. beta-Adrenergic Blockade for the Treatment of Hyperthyroidism. <i>Am J Med</i>. 1992;93(1):61-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/1352658/pubmed" id="1352658" target="_blank">1352658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8956349">
<a name="8956349"></a>Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. <i>Pharmacopsychiatry</i>. 1996;29(6):201-211. doi:10.1055/s-2007-979572<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/8956349/pubmed" id="8956349" target="_blank">8956349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. <i>Hypertension</i>. Published online November 15, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2903871">
<a name="2903871"></a>Gold MH, Holy AK, Roenigk HH Jr. Beta-Blocking Drugs and Psoriasis. A Review of Cutaneous Side Effects and Retrospective Analysis of Their Effects on Psoriasis. <i>J Am Acad Dermatol</i>. 1988;19(5, pt 1):837-841.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2903871/pubmed" id="2903871" target="_blank">2903871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20233272">
<a name="20233272"></a>Goldenberg I, Bradley J, Moss A, et al; International LQTS Registry Investigators. Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient management. <i>J Cardiovasc Electrophysiol</i>. 2010;21(8):893-901. doi:10.1111/j.1540-8167.2010.01737.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/20233272/pubmed" id="20233272" target="_blank">20233272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.1">
<a name="Golightly.1"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys. </i>Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3723506">
<a name="3723506"></a>Gouet D, Marechaud R, Aucouturier P, Touchard G, Sudre Y, Preud'homme JL. Atenolol induced systemic lupus erythematosus syndrome.<i> J Rheumatol</i>. 1986;13(2):446-447.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/3723506/pubmed" id="3723506" target="_blank">3723506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30600979">
<a name="30600979"></a>Ha H, Gonzalez A. Migraine headache prophylaxis. <i>Am Fam Physician</i>. 2019;99(1):17-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/30600979/pubmed" id="30600979" target="_blank">30600979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10085663">
<a name="10085663"></a>Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series. <i>J Am Dent Assoc.</i> 1999;130(3):397-407.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/10085663/pubmed" id="10085663" target="_blank">10085663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15601802">
<a name="15601802"></a>Hebert MF, Carr DB, Anderson GD, et al. Pharmacokinetics and Pharmacodynamics of Atenolol During Pregnancy and Postpartum. <i>J Clin Pharmacol</i>. 2005;45(1):25-33.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15601802/pubmed" id="15601802" target="_blank">15601802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549646">
<a name="16549646"></a>Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary. A Collaborative Report of the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). <i>Circulation.</i> 2006;113(11):1474-1547.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/16549646/pubmed" id="16549646" target="_blank">16549646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt DW, Bhamra R, Thorley KJ, et al. High performance liquid chromatographic measurement of atenolol: placental transfer and expression in milk. Proceedings of the British Pharmacological Society: University of Strathclyde, Glasgow. 31st March, 1st-2nd April, 1982. <i>Br J Clin Pharmacol</i>. 1982;14(1):148P.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33432057">
<a name="33432057"></a>Huang KY, Tseng PT, Wu YC, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. <i>Sci Rep</i>. 2021;11(1):452. doi:10.1038/s41598-020-79837-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/33432057/pubmed" id="33432057" target="_blank">33432057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2873379">
<a name="2873379"></a>ISIS-1 (First International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. <i>Lancet</i>. 1986;2(8498):57-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2873379/pubmed" id="2873379" target="_blank">2873379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322642">
<a name="36322642"></a>Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. <i>Circulation.</i> 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/36322642/pubmed" id="36322642" target="_blank">36322642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1977302">
<a name="1977302"></a>Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. <i>Am J Cardiol</i>. 1990;66(9):21C-23C. doi:10.1016/0002-9149(90)90758-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/1977302/pubmed" id="1977302" target="_blank">1977302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2014;130(23):e199-267.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019:S1547-5271(19)30037-2. doi:10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27310994">
<a name="27310994"></a>Ji Y, Wang Q, Chen S, et al. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. <i>Medicine (Baltimore)</i>. 2016;95(24):e3908. doi:10.1097/MD.0000000000003908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/27310994/pubmed" id="27310994" target="_blank">27310994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kannam.1">
<a name="Kannam.1"></a>Kannam JP, Gersh BJ. Beta blockers in the management of chronic coronary syndrome. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7461026">
<a name="7461026"></a>Kirch W, Köhler H, Mutschler E, Schäfer M. Pharmacokinetics of atenolol in relation to renal function. <i>Eur J Clin Pharmacol</i>. 1981;19(1):65-71. doi:10.1007/BF00558387<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/7461026/pubmed" id="7461026" target="_blank">7461026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Geme Ill JW, Schor NF, Behrman RE, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Elsevier Saunders; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376011">
<a name="6376011"></a>Kleinbaum J, Shamoon H. Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects. <i>Diabetes Care</i>. 1984;7(2):155-162. doi:10.2337/diacare.7.2.155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6376011/pubmed" id="6376011" target="_blank">6376011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117400">
<a name="12117400"></a>Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. <i>JAMA</i>. 2002;288(3):351-357. doi:10.1001/jama.288.3.351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/12117400/pubmed" id="12117400" target="_blank">12117400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865151">
<a name="2865151"></a>Koella WP. CNS-related (side-)effects of beta-blockers with special reference to mechanisms of action. <i>Eur J Clin Pharmacol</i>. 1985;(28)(suppl):55-63. doi:10.1007/BF00543711<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2865151/pubmed" id="2865151" target="_blank">2865151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2878741">
<a name="2878741"></a>Kostis JB, Rosen RC. Central nervous system effects of beta-adrenergic-blocking drugs: the role of ancillary properties. <i>Circulation</i>. 1987;75(1):204-212. doi:10.1161/01.cir.75.1.204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2878741/pubmed" id="2878741" target="_blank">2878741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2863754">
<a name="2863754"></a>Kraus ML, Gottlieb LD, Horwitz RI, et al. Randomized Clinical Trial of Atenolol in Patients With Alcohol Withdrawal. <i>N Engl J Med</i>. 1985;313(15):905-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2863754/pubmed" id="2863754" target="_blank">2863754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12486439">
<a name="12486439"></a>Krittayaphong R, Bhuripanyo K, Punlee K, Kangkagate C, Chaithiraphan S. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. <i>Am Heart J</i>. 2002;144(6):e10. doi:10.1067/mhj.2002.125516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/12486439/pubmed" id="12486439" target="_blank">12486439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25405392">
<a name="25405392"></a>Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. <i>N Engl J Med</i>. 2014;371(22):2061-2071. doi:10.1056/NEJMoa1404731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/25405392/pubmed" id="25405392" target="_blank">25405392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17892982">
<a name="17892982"></a>Lacro RV, Dietz HC, Wruck LM, et al. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. <i>Am Heart J</i>. 2007;154(4):624-631. doi:10.1016/j.ahj.2007.06.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/17892982/pubmed" id="17892982" target="_blank">17892982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-85053">
<a name="85053"></a>Lager I, Blohmé G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. <i>Lancet</i>. 1979;1(8114):458-462. doi:10.1016/s0140-6736(79)90821-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/85053/pubmed" id="85053" target="_blank">85053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7669259">
<a name="7669259"></a>Lang DM. Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers. <i>Drug Saf.</i> 1995;12(5):299-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/7669259/pubmed" id="7669259" target="_blank">7669259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18377773">
<a name="18377773"></a>Lang DM. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?<i> Curr Allergy Asthma Rep</i>. 2008;8(1):37-44. doi:10.1007/s11882-008-0008-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/18377773/pubmed" id="18377773" target="_blank">18377773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6339540">
<a name="6339540"></a>Lauridsen UB, Christensen NJ, Lyngsøe J. Effects of nonselective and beta-1-selective blockade on glucose metabolism and hormone responses during insulin-induced hypoglycemia in normal man.<i> J Clin Endocrinol Metab</i>. 1983;56(5):876-882. doi:10.1210/jcem-56-5-876<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6339540/pubmed" id="6339540" target="_blank">6339540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6127219">
<a name="6127219"></a>Lawrence DS, Sahay JN, Chatterjee SS, Cruickshank JM. Asthma and beta-blockers. <i>Eur J Clin Pharmacol</i>. 1982;22(6):501-509. doi:10.1007/BF00609622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6127219/pubmed" id="6127219" target="_blank">6127219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37093">
<a name="37093"></a>Lederballe Pedersen O, Mikkelsen E, Lanng Nielsen J, Christensen NJ. Abrupt withdrawal of beta-blocking agents in patients with arterial hypertension. Effect on blood pressure, heart rate and plasma catecholamines and prolactin. <i>Eur J Clin Pharmacol</i>. 1979;15(3):215-217. doi:10.1007/BF00563108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/37093/pubmed" id="37093" target="_blank">37093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22267844">
<a name="22267844"></a>Levine GN, Steinke EE, Bakaeen FG, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Quality of Care and Outcomes Research. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. <i>Circulation</i>. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/22267844/pubmed" id="22267844" target="_blank">22267844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3017391">
<a name="3017391"></a>Lichter I, Richardson PJ, Wyke MA. Differential effects of atenolol and enalapril on memory during treatment for essential hypertension. <i>Br J Clin Pharmacol</i>. 1986;21(6):641-645. doi:10.1111/j.1365-2125.1986.tb05228.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/3017391/pubmed" id="3017391" target="_blank">3017391</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16049209">
<a name="16049209"></a>Lindenauer PK, Pekow P, Wang K, et al. Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery. <i>N Engl J Med</i>. 2005;353(4):349-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/16049209/pubmed" id="16049209" target="_blank">16049209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27390282">
<a name="27390282"></a>Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. <i>Eur Respir J</i>. 2016;48(3):880-888. doi:10.1183/13993003.01847-2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/27390282/pubmed" id="27390282" target="_blank">27390282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28182127">
<a name="28182127"></a>Liu X, Lou X, Cheng X, Meng Y. Impact of metoprolol treatment on mental status of chronic heart failure patients with neuropsychiatric disorders. <i>Drug Des Devel Ther</i>. 2017;11:305-312. doi:10.2147/DDDT.S124497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/28182127/pubmed" id="28182127" target="_blank">28182127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15288162">
<a name="15288162"></a>López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. <i>Eur Heart J</i>. 2004;25(15):1341-1362. doi:10.1016/j.ehj.2004.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15288162/pubmed" id="15288162" target="_blank">15288162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27899939">
<a name="27899939"></a>Lu HT, Kam J, Nordin RB, et al. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. <i>J Geriatr Cardiol</i>. 2016;13(9):749-759. doi:10.11909/j.issn.1671-5411.2016.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/27899939/pubmed" id="27899939" target="_blank">27899939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29870669">
<a name="29870669"></a>Lwin EMP, Gerber C, Leggett C, et al. Estimation of atenolol transfer into milk and infant exposure during its use in lactating women. <i>J Hum Lact</i>. 2018;34(3):592-599.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/29870669/pubmed" id="29870669" target="_blank">29870669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.1">
<a name="Manolis.1"></a>Manolis AS. Premature ventricular complexes: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 31, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19660690">
<a name="19660690"></a>Marcus GM, Glidden DV, Polonsky B, et al; Multidisciplinary Study of Right Ventricular Dysplasia Investigators. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. <i>J Am Coll Cardiol</i>. 2009;54(7):609-615. doi:10.1016/j.jacc.2009.04.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/19660690/pubmed" id="19660690" target="_blank">19660690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6109">
<a name="6109"></a>Marshall AJ, Roberts CJ, Barritt DW. Raynaud's phenomenon as side effect of beta-blockers in hypertension. <i>Br Med J</i>. 1976;1(6024):1498-1499. doi:10.1136/bmj.1.6024.1498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6109/pubmed" id="6109" target="_blank">6109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562933">
<a name="9562933"></a>Mayer S, Hillis LD. Prinzmetal's variant angina. <i>Clin Cardiol</i>. 1998;21(4):243-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/9562933/pubmed" id="9562933" target="_blank">9562933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1969642">
<a name="1969642"></a>McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. <i>Pharmacol Ther</i>. 1990;46(2):163-197. doi:10.1016/0163-7258(90)90092-g<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/1969642/pubmed" id="1969642" target="_blank">1969642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7408390">
<a name="7408390"></a>McAinsh J, Holmes BF, Smith S, Hood D, Warren D. Atenolol kinetics in renal failure. <i>Clin Pharmacol Ther</i>. 1980;28(3):302-309. doi:10.1038/clpt.1980.166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/7408390/pubmed" id="7408390" target="_blank">7408390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8662045">
<a name="8662045"></a>Mehta AV, Subrahmanyam AB, Anand R. Long-term efficacy and safety of atenolol for supraventricular tachycardia in children.<i> Pediatr Cardiol</i>. 1996;17(4):231-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/8662045/pubmed" id="8662045" target="_blank">8662045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2861072">
<a name="2861072"></a>Mills GA, Horn JR. Beta-blockers and glucose control. <i>Drug Intell Clin Pharm</i>. 1985;19(4):246-251. doi:10.1177/106002808501900401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2861072/pubmed" id="2861072" target="_blank">2861072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3278028">
<a name="3278028"></a>Mito RS, Yagiela JA. Hypertensive response to levonordefrin in a patient receiving propranolol: report of a case. <i>J Am Dent Assoc.</i> 1988;116(1):55-57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/3278028/pubmed" id="3278028" target="_blank">3278028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24202435">
<a name="24202435"></a>Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. <i>Chest</i>. 2014;145(4):779-786. doi:10.1378/chest.13-1235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24202435/pubmed" id="24202435" target="_blank">24202435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10673253">
<a name="10673253"></a>Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. <i>Circulation</i>. 2000;101(6):616-623.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/10673253/pubmed" id="10673253" target="_blank">10673253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIH.1">
<a name="NIH.1"></a>National Heart, Lung, and Blood Institute, National Institutes of Health. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. <i>Clinical Practice Guidelines</i>, 2011. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15286277">
<a name="15286277"></a>National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2004;114(2 suppl 4th report):555-576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15286277/pubmed" id="15286277" target="_blank">15286277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24155101">
<a name="24155101"></a>Nicolai MP, Liem SS, Both S, et al. A review of the positive and negative effects of cardiovascular drugs on sexual function: a proposed table for use in clinical practice. <i>Neth Heart J</i>. 2014;22(1):11-19. doi:10.1007/s12471-013-0482-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24155101/pubmed" id="24155101" target="_blank">24155101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37238395">
<a name="37238395"></a>Oeffl N, Schober L, Faudon P, et al. Antiarrhythmic drug dosing in children-review of the literature. <i>Children (Basel)</i>. 2023;10(5):847. doi:10.3390/children10050847<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/37238395/pubmed" id="37238395" target="_blank">37238395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33692921">
<a name="33692921"></a>Oo KT, Yee HW. A case of reversible atrioventricular block potentially associated with atenolol-induced hyperkalemia. <i>Cureus</i>. 2021;13(2):e13151. doi:10.7759/cureus.13151<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/33692921/pubmed" id="33692921" target="_blank">33692921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530749">
<a name="22530749"></a>Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. <i>Pacing Clin Electrophysiol</i>. 2012;35(7):804-810. doi:10.1111/j.1540-8159.2012.03410.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/22530749/pubmed" id="22530749" target="_blank">22530749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26399663">
<a name="26399663"></a>Page RL, Joglar JA, Caldwell MA, et al; Evidence Review Committee Chair. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i>. 2016;133(14):e506-7e54. doi:10.1161/CIR.0000000000000311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/26399663/pubmed" id="26399663" target="_blank">26399663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6376017">
<a name="6376017"></a>Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. <i>Diabetes Care</i>. 1984;7(3):243-247. doi:10.2337/diacare.7.3.243<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6376017/pubmed" id="6376017" target="_blank">6376017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683887">
<a name="22683887"></a>Pringsheim T, Davenport W, Mackie G, et al; Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. <i>Can J Neurol Sci</i>. 2012;39(2 suppl 2):S1-S59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/22683887/pubmed" id="22683887" target="_blank">22683887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2897302">
<a name="2897302"></a>Proclemer A, Gradnik R, Savonitto S, Feruglio GA. Electrophysiological effects of bisoprolol. <i>Eur Heart J</i>. 1987;8(suppl M):81-85. doi:10.1093/eurheartj/8.suppl_m.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2897302/pubmed" id="2897302" target="_blank">2897302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2450898">
<a name="2450898"></a>Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. <i>J Clin Pharmacol</i>. 1988;28(1):6-21. doi:10.1002/j.1552-4604.1988.tb03095.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2450898/pubmed" id="2450898" target="_blank">2450898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1968518">
<a name="1968518"></a>Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. <i>JAMA</i>. 1990;263(12):1653-1657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/1968518/pubmed" id="1968518" target="_blank">1968518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1679624">
<a name="1679624"></a>Radack K, Deck C. Beta-Adrenergic Blocker Therapy Does Not Worsen Intermittent Claudication in Subjects With Peripheral Arterial Disease. A Meta-Analysis of Randomized Controlled Trials. <i>Arch Intern Med</i>. 1991;151(9):1769-1776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/1679624/pubmed" id="1679624" target="_blank">1679624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6125187">
<a name="6125187"></a>Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. <i>Br J Clin Pharmacol</i>. 1982;13(Suppl 2):345S-351S. doi:10.1111/j.1365-2125.1982.tb01939.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6125187/pubmed" id="6125187" target="_blank">6125187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8438752">
<a name="8438752"></a>Reed CM, Fox ME, Alpert BS. Aortic biomechanical properties in pediatric patients with the Marfan syndrome, and the effects of atenolol. <i>Am J Cardiol</i>. 1993;71(7):606-608.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/8438752/pubmed" id="8438752" target="_blank">8438752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association; American College of Cardiology; and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosenson.1">
<a name="Rosenson.1"></a>Rosenson RS, Reeder GS, Kennedy HL. Acute myocardial infarction: role of beta blocker therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 30, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross DS. Beta blockers in the treatment of hyperthyroidism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27521067">
<a name="27521067"></a>Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. <i>Thyroid</i>. 2016;26(10):1343-1421. doi:10.1089/thy.2016.0229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/27521067/pubmed" id="27521067" target="_blank">27521067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6661350">
<a name="6661350"></a>Rubin PC, Butters L, Reynolds B, Evans J, Sumner D, Low RA, Reid JL. Atenolol elimination in the neonate. <i>Br J Clin Pharmacol</i>. 1983;16(6):659-662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6661350/pubmed" id="6661350" target="_blank">6661350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6487486">
<a name="6487486"></a>Salahudeen AK, Wilkinson R, McAinsh J, Bateman DN. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis. <i>Br J Clin Pharmacol</i>. 1984;18(3):457-460. doi:10.1111/j.1365-2125.1984.tb02490.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6487486/pubmed" id="6487486" target="_blank">6487486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12519582">
<a name="12519582"></a>Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. <i>Cochrane Database Syst Rev</i>. 2002;(4):CD002992. doi:10.1002/14651858.CD002992<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/12519582/pubmed" id="12519582" target="_blank">12519582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17239714">
<a name="17239714"></a>Sauer AJ, Moss AJ, McNitt S, et al. Long QT syndrome in adults. <i>J Am Coll Cardiol</i>. 2007;49(3):329-337. doi:10.1016/j.jacc.2006.08.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/17239714/pubmed" id="17239714" target="_blank">17239714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024438">
<a name="23024438"></a>Scheer FA, Morris CJ, Garcia JI, et al. Repeated melatonin supplementation improves sleep in hypertensive patients treated with beta-blockers: a randomized controlled trial. <i>Sleep</i>. 2012;35(10):1395-1402. doi:10.5665/sleep.2122<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/23024438/pubmed" id="23024438" target="_blank">23024438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15872205">
<a name="15872205"></a>Schön MP, Boehncke WH. Psoriasis. <i>N Eng J Med</i>. 2005;352(18):1899-1912.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15872205/pubmed" id="15872205" target="_blank">15872205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Schwedt.1">
<a name="Schwedt.1"></a>Schwedt TJ, Garza I. Preventive treatment of episodic migraine in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34419523">
<a name="34419523"></a>Sebaratnam DF, Rodríguez Bandera AL, Wong LF, Wargon O. Infantile hemangioma. Part 2: management. <i>J Am Acad Dermatol</i>. 2021;85(6):1395-1404. doi:10.1016/j.jaad.2021.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/34419523/pubmed" id="34419523" target="_blank">34419523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622464">
<a name="28622464"></a>Semet M, Paci M, Saïas-Magnan J, et al. The impact of drugs on male fertility: a review. <i>Andrology</i>. 2017;5(4):640-663. doi:10.1111/andr.12366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/28622464/pubmed" id="28622464" target="_blank">28622464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26252585">
<a name="26252585"></a>Silberstein SD. Preventive migraine treatment. <i>Continuum (Minneap Minn)</i>. 2015;21(4)(Headache):973-989. doi:10.1212/CON.0000000000000199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/26252585/pubmed" id="26252585" target="_blank">26252585</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22529202">
<a name="22529202"></a>Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. <i>Neurology</i>. 2012;78(17):1337-1345. doi:10.1212/WNL.0b013e3182535d20<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/22529202/pubmed" id="22529202" target="_blank">22529202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14585251">
<a name="14585251"></a>Silvestri A, Galetta P, Cerquetani E, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. <i>Eur Heart J</i>. 2003;24(21):1928-1932. doi:10.1016/j.ehj.2003.08.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/14585251/pubmed" id="14585251" target="_blank">14585251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simons.1">
<a name="Simons.1"></a>Simons M, Breall JA. Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22433576">
<a name="22433576"></a>Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control. <i>Can J Cardiol</i>. 2012;28(2):125-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/22433576/pubmed" id="22433576" target="_blank">22433576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22052934">
<a name="22052934"></a>Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i>. 2011;124(22):2458-2473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/22052934/pubmed" id="22052934" target="_blank">22052934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31113373">
<a name="31113373"></a>Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting the Burden: the Global Campaign against Headache.<i> J Headache Pain</i>. 2019;20(1):57. doi:10.1186/s10194-018-0899-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/31113373/pubmed" id="31113373" target="_blank">31113373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tenormin.2">
<a name="Tenormin.2"></a>Tenormin (atenolol) [prescribing information]. Norwich, NJ: Norwich Pharmaceuticals Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tenormin.1">
<a name="Tenormin.1"></a>Tenormin (atenolol) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34331033">
<a name="34331033"></a>Terentes-Printzios D, Ioakeimidis N, Rokkas K, Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. <i>Nat Rev Cardiol</i>. 2022;19(1):59-74. doi:10.1038/s41569-021-00593-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/34331033/pubmed" id="34331033" target="_blank">34331033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29519953">
<a name="29519953"></a>Tieu A, Velenosi TJ, Kucey AS, Weir MA, Urquhart BL. <i>β</i>-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial. <i>Clin J Am Soc Nephrol</i>. 2018;13(4):604-611. doi:10.2215/CJN.07470717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/29519953/pubmed" id="29519953" target="_blank">29519953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2882832">
<a name="2882832"></a>Toogood JH. Beta-blocker therapy and the risk of anaphylaxis. <i>CMAJ</i>. 1987;136(9):929-933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2882832/pubmed" id="2882832" target="_blank">2882832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2741832">
<a name="2741832"></a>Trippel DL, Gillette PC.Atenolol in Children With Supraventricular Tachycardia. <i>Am J Cardiol</i>. 1989;64(3):233-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2741832/pubmed" id="2741832" target="_blank">2741832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28559400">
<a name="28559400"></a>Tsujimoto T, Sugiyama T, Shapiro MF, Noda M, Kajio H. Risk of cardiovascular events in patients with diabetes mellitus on β-blockers. <i>Hypertension</i>. 2017;70(1):103-110. doi:10.1161/HYPERTENSIONAHA.117.09259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/28559400/pubmed" id="28559400" target="_blank">28559400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9732338">
<a name="9732338"></a>UK Prospective Diabetes Study Group. Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39. <i>BMJ</i>. 1998;317(7160):713-720.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/9732338/pubmed" id="9732338" target="_blank">9732338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6624977">
<a name="6624977"></a>Viadero JJ, Wong SH, White WB. Acute psychotic behavior associated with atenolol. <i>Am J Psychiatry</i>. 1983;140(10):1382. doi:10.1176/ajp.140.10.1382b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/6624977/pubmed" id="6624977" target="_blank">6624977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32073535">
<a name="32073535"></a>Viigimaa M, Vlachopoulos C, Doumas M, et al; European Society of Hypertension Working Group on Sexual Dysfunction. Update of the position paper on arterial hypertension and erectile dysfunction. <i>J Hypertens</i>. 2020;38(7):1220-1234. doi:10.1097/HJH.0000000000002382<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/32073535/pubmed" id="32073535" target="_blank">32073535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vue.1">
<a name="Vue.1"></a>Vue MH, Setter SM. Drug-induced glucose alterations part 1: drug-induced hypoglycemia. <i>Diabetes Spectrum. </i>2011. https://doi.org/10.2337/diaspect.24.3.171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/Vue.1/pubmed" id="Vue.1" target="_blank">Vue.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2141782">
<a name="2141782"></a>Wakefield PE, Berger TG, James WD. Atenolol-induced pustular psoriasis. <i>Arch Dermatol</i>. 1990;126(7):968-969. doi:10.1001/archderm.126.7.968<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2141782/pubmed" id="2141782" target="_blank">2141782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1981318">
<a name="1981318"></a>Walden RJ, Tomlinson B, Graham B, Liu JB, Prichard BN. Withdrawal phenomena after atenolol and bopindolol: haemodynamic responses in healthy volunteers. <i>Br J Clin Pharmacol</i>. 1990;30(4):557-565. doi:10.1111/j.1365-2125.1990.tb03813.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/1981318/pubmed" id="1981318" target="_blank">1981318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3970785">
<a name="3970785"></a>Walker PR, Marshall AJ, Farr S, Bauminger B, Walters G, Barritt DW. Abrupt withdrawal of atenolol in patients with severe angina. Comparison with the effects of treatment. <i>Br Heart J</i>. 1985;53(3):276-282. doi:10.1136/hrt.53.3.276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/3970785/pubmed" id="3970785" target="_blank">3970785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9447850">
<a name="9447850"></a>Wallace A, Layug B, Tateo I, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. <i>Anesthesiology</i>. 1998;88(1):7-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/9447850/pubmed" id="9447850" target="_blank">9447850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21173346">
<a name="21173346"></a>Wann SL, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation.</i> 2011;123(1):104-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/21173346/pubmed" id="21173346" target="_blank">21173346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7306435">
<a name="7306435"></a>Webster J, Hawksworth GM, Barber HE, Jeffers TA, Petrie JC. Withdrawal of long-term therapy with atenolol in hypertensive patients. <i>Br J Clin Pharmacol</i>. 1981;12(2):211-214. doi:10.1111/j.1365-2125.1981.tb01202.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/7306435/pubmed" id="7306435" target="_blank">7306435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2865153">
<a name="2865153"></a>Westerlund A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers. <i>Eur J Clin Pharmacol</i>. 1985;(28)(suppl):73-76. doi:10.1007/BF00543714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2865153/pubmed" id="2865153" target="_blank">2865153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133354">
<a name="29133354"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Hypertension</i>. 2018;71(6):1269-1324. doi:10.1161/HYP.0000000000000066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/29133354/pubmed" id="29133354" target="_blank">29133354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2871333">
<a name="2871333"></a>Wong DG, Spence JD, Lamki L, et al. Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics. <i>Lancet</i>. 1986;1(8488):997-1001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/2871333/pubmed" id="2871333" target="_blank">2871333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wright.1">
<a name="Wright.1"></a>Wright MJ, Connolly HM. Management of Marfan syndrome and related syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7911769">
<a name="7911769"></a>Wynn RL. Epinephrine Interactions With Beta-Blockers. <i>Gen Dent</i>. 1994;42(1):16, 18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/7911769/pubmed" id="7911769" target="_blank">7911769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12463630">
<a name="12463630"></a>Yilmaz MB, Turhan H, Akin Y, Kisacik HL, Korkmaz S. Beta-blocker-induced psoriasis: a rare side effect--a case report. <i>Angiology</i>. 2002;53(6):737-739. doi:10.1177/000331970205300617<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/12463630/pubmed" id="12463630" target="_blank">12463630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zacharias.1">
<a name="Zacharias.1"></a>Zacharias FJ. Atenolol compared with other beta-blocking agents. <i>Proc. Roy. Soc. Med</i>. 1977. https://journals.sagepub.com/doi/pdf/10.1177/00359157770700S511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/Zacharias.1/pubmed" id="Zacharias.1" target="_blank">Zacharias.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atenolol-pediatric-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12848 Version 548.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
